Sunovion Pharmaceuticals Inc.'s Latuda® (lurasidone HCl) Label Updated With Expanded Dosing Range Providing Added Flexibility for the Treatment of Patients With Schizophrenia
5/7/2012 9:13:47 AM
MARLBOROUGH, Mass.--(BUSINESS WIRE)--Sunovion Pharmaceuticals Inc. today announced that the U.S. Food and Drug Administration (FDA) has approved an expanded dose range for LATUDA in the treatment of adult patients with schizophrenia. The FDA decision followed a review of the supplemental New Drug Application (sNDA), which was submitted in June 2011.
comments powered by